Home  »  Equity Investing   »  Blonder Tongue Laboratories Inc. (BDR) stock gains...

Blonder Tongue Laboratories Inc. (BDR) stock gains in the after-hour session. Why is it so?

Blonder Tongue Laboratories Inc. (BDR) stock surged by 14.05% at the last trading close while the BDR stock price continued to rise by 12.32% in the after-hours trading session. As of now, there is no recent news available regarding this gain in BDR stock. BDR is the oldest telephone and cable television video transmission equipment pioneer and developer in the United States. Blonder Tongue Labs is a U.S.-based research and manufacturing company with a track record in producing ultra-reliable material

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free


Important Past Event

On April 7, 2021, BDR It was announced that it had obtained notification from NYSE American LLC that it was not in compliance with Section 1003(a)(i) of the NYSE American Company Guide’s persisted listing standard (the “Company Guide”). If a publicly traded corporation has stockholders’ equity of less than $2 million and has registered losses from operating operations and/or net losses in two of the last three fiscal years, the provision applies.

BDR submitted a formal financial proposal to NYSE American in order to restore compliance with the listing requirement set out in Section 1003(a)(iii), and the Company obtained notification on August 27, 2020, that its plan had been approved and that the Company had been given a plan period until December 10, 2021. The deadline for BDR to resume compliance with the listing requirements is December 10, 2021, and it extends to the noncompliance cited in all three NYSE American notices. As a consequence, by the date, BDR would be in agreement with Sections 1003(a)(i), 1003(a)(ii), and 1003(a)(iii).


It has been observed that BDR has not reached some aspects of the near-term targets contained in its roadmap to restore compliance with the listing requirements, as disclosed in the Company’s disclosures with the Securities and Exchange Commission, owing to the ongoing impact of the COVID-19 pandemic.

Leave a Comment

Your email address will not be published. Required fields are marked *

Most Popular

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Related Posts

Biotech Stocks to Buy for Sep-2021

Biotechnology (biotech) refers to the use of microbes and cellular biology in health-related research and development. It is not just therapies that biotechnology companies develop.




Download Free eBook For


100% free. stop anytime no spam